Insider Selling: Stoke Therapeutics (NASDAQ:STOK) General Counsel Sells 2,292 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 2,292 shares of Stoke Therapeutics stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $30.65, for a total value of $70,249.80. Following the transaction, the general counsel directly owned 19,612 shares in the company, valued at approximately $601,107.80. The trade was a 10.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Jonathan Allan also recently made the following trade(s):

• On Tuesday, December 2nd, Jonathan Allan sold 2,284 shares of Stoke Therapeutics stock. The shares were sold at an average price of $29.78, for a total value of $68,017.52.
• On Friday, October 3rd, Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock. The stock was sold at an average price of $25.07, for a total value of $250,700.00.

Stoke Therapeutics Stock Performance

NASDAQ STOK traded up $1.15 during trading hours on Wednesday, hitting $30.96. The company had a trading volume of 665,349 shares, compared to its average volume of 1,025,254. The firm has a 50 day simple moving average of $28.58 and a 200 day simple moving average of $19.53. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $38.69. The firm has a market capitalization of $1.77 billion, a price-to-earnings ratio of 46.21 and a beta of 1.14.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). The business had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%. On average, research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. CANADA LIFE ASSURANCE Co grew its stake in shares of Stoke Therapeutics by 12.3% in the third quarter. CANADA LIFE ASSURANCE Co now owns 11,978 shares of the company’s stock worth $296,000 after acquiring an additional 1,313 shares during the last quarter. Polar Capital Holdings Plc increased its position in shares of Stoke Therapeutics by 49.8% during the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock valued at $31,102,000 after acquiring an additional 439,824 shares in the last quarter. Parkman Healthcare Partners LLC bought a new position in Stoke Therapeutics in the 3rd quarter valued at approximately $5,875,000. Nomura Holdings Inc. bought a new stake in shares of Stoke Therapeutics in the 3rd quarter worth $1,908,000. Finally, Millennium Management LLC raised its stake in shares of Stoke Therapeutics by 199.3% in the third quarter. Millennium Management LLC now owns 61,048 shares of the company’s stock worth $1,435,000 after purchasing an additional 40,652 shares during the last quarter.

Wall Street Analyst Weigh In

STOK has been the topic of several research reports. BTIG Research restated a “buy” rating and set a $39.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, November 5th. Canaccord Genuity Group increased their price target on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Wedbush upped their price objective on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the company an “outperform” rating in a research note on Wednesday, November 5th. Chardan Capital upgraded shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. Finally, JPMorgan Chase & Co. lifted their price objective on Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $31.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.